468 related articles for article (PubMed ID: 19886322)
1. Clinical outcomes in peritoneal dialysis: impact of continuous quality provement initiatives.
Qamar M; Sheth H; Bender FH; Piraino B
Adv Perit Dial; 2009; 25():76-9. PubMed ID: 19886322
[TBL] [Abstract][Full Text] [Related]
2. Comparison of gentamicin and mupirocin in the prevention of exit-site infection and peritonitis in peritoneal dialysis.
Mahaldar A; Weisz M; Kathuria P
Adv Perit Dial; 2009; 25():56-9. PubMed ID: 19886318
[TBL] [Abstract][Full Text] [Related]
3. Randomized, double-blind trial of antibiotic exit site cream for prevention of exit site infection in peritoneal dialysis patients.
Bernardini J; Bender F; Florio T; Sloand J; Palmmontalbano L; Fried L; Piraino B
J Am Soc Nephrol; 2005 Feb; 16(2):539-45. PubMed ID: 15625071
[TBL] [Abstract][Full Text] [Related]
4. Fivefold reduction in peritonitis using a multifaceted continuous quality initiative program.
Borg D; Shetty A; Williams D; Faber MD
Adv Perit Dial; 2003; 19():202-5. PubMed ID: 14763063
[TBL] [Abstract][Full Text] [Related]
5. The effectiveness of mupirocin preventing Staphylococcus aureus in catheter-related infections in peritoneal dialysis.
Thodis E; Passadakis P; Panagoutsos S; Bacharaki D; Euthimiadou A; Vargemezis V
Adv Perit Dial; 2000; 16():257-61. PubMed ID: 11045306
[TBL] [Abstract][Full Text] [Related]
6. Exit site infections: systematic microbiologic and quality control are needed.
Freitas C; Rodrigues A; Carvalho MJ; Cabrita A
Adv Perit Dial; 2009; 25():26-31. PubMed ID: 19886313
[TBL] [Abstract][Full Text] [Related]
7. Outcome and complications in peritoneal dialysis patients: a five-year single center experience.
Alwakeel JS; Alsuwaida A; Askar A; Memon N; Usama S; Alghonaim M; Feraz NA; Shah IH; Wilson H
Saudi J Kidney Dis Transpl; 2011 Mar; 22(2):245-51. PubMed ID: 21422621
[TBL] [Abstract][Full Text] [Related]
8. Decrease in infections with the introduction of mupirocin cream at the peritoneal dialysis catheter exit site.
Uttley L; Vardhan A; Mahajan S; Smart B; Hutchison A; Gokal R
J Nephrol; 2004; 17(2):242-5. PubMed ID: 15293524
[TBL] [Abstract][Full Text] [Related]
9. Do topical antibiotics reduce exit site infection rates and peritonitis episodes in peritoneal dialysis patients? The Pan Thames Renal Audit.
Davenport A;
J Nephrol; 2012; 25(5):819-24. PubMed ID: 22241640
[TBL] [Abstract][Full Text] [Related]
10. The impact of topical mupirocin on peritoneal dialysis infection rates in Singapore General Hospital.
Lim CT; Wong KS; Foo MW
Nephrol Dial Transplant; 2005 Aug; 20(8):1702-6. PubMed ID: 15855200
[TBL] [Abstract][Full Text] [Related]
11. Technique survival with Serratia peritonitis.
Hiremath S; Biyani M
Adv Perit Dial; 2006; 22():73-6. PubMed ID: 16983944
[TBL] [Abstract][Full Text] [Related]
12. Effect of once-a-week vs thrice-a-week application of mupirocin on methicillin and mupirocin resistance in peritoneal dialysis patients: three years of experience.
Cavdar C; Saglam F; Sifil A; Celik A; Atay T; Gungor O; Ozder A; Gulay Z; Camsari T
Ren Fail; 2008; 30(4):417-22. PubMed ID: 18569916
[TBL] [Abstract][Full Text] [Related]
13. Mupirocin application at the exit site in peritoneal dialysis patients: five years of experience.
Aykut S; Caner C; Ozkan G; Ali C; Tugba A; Zeynep G; Taner C
Ren Fail; 2010 Jan; 32(3):356-61. PubMed ID: 20370452
[TBL] [Abstract][Full Text] [Related]
14. Prevention of peritoneal dialysis-related infections.
Nessim SJ
Semin Nephrol; 2011 Mar; 31(2):199-212. PubMed ID: 21439433
[TBL] [Abstract][Full Text] [Related]
15. The Effect of Exit-Site Antibacterial Honey Versus Nasal Mupirocin Prophylaxis on the Microbiology and Outcomes of Peritoneal Dialysis-Associated Peritonitis and Exit-Site Infections: A Sub-Study of the Honeypot Trial.
Zhang L; Badve SV; Pascoe EM; Beller E; Cass A; Clark C; de Zoysa J; Isbel NM; McTaggart S; Morrish AT; Playford EG; Scaria A; Snelling P; Vergara LA; Hawley CM; Johnson DW;
Perit Dial Int; 2015 Dec; 35(7):712-21. PubMed ID: 26224790
[TBL] [Abstract][Full Text] [Related]
16. The impact of topical mupirocin on peritoneal dialysis infection in Singapore General Hospital.
Lim CT; Wong KS; Foo MW
Nephrol Dial Transplant; 2005 Oct; 20(10):2202-6. PubMed ID: 16046516
[TBL] [Abstract][Full Text] [Related]
17. Peritoneal dialysis in chronic renal failure patients over 65 years of age.
Ferńandez MA; Ortiz AM; Valenzuela M; Morales RA
Adv Perit Dial; 2004; 20():128-31. PubMed ID: 15384812
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Topical Chlorhexidine and Mupirocin for the Prevention of Exit-Site Infection in Incident Peritoneal Dialysis Patients.
Htay H; Johnson DW; Wu SY; Oei EL; Foo MWY; Choo JCJ
Perit Dial Int; 2017; 37(3):266-272. PubMed ID: 28183858
[TBL] [Abstract][Full Text] [Related]
19. Long-Term Exit-Site Gentamicin Prophylaxis and Gentamicin Resistance in a Peritoneal Dialysis Program.
Chen SS; Sheth H; Piraino B; Bender F
Perit Dial Int; 2016; 36(4):387-9. PubMed ID: 26634567
[TBL] [Abstract][Full Text] [Related]
20. Mupirocin for preventing exit-site infection and peritonitis in patients undergoing peritoneal dialysis.
Xu G; Tu W; Xu C
Nephrol Dial Transplant; 2010 Feb; 25(2):587-92. PubMed ID: 19679557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
